SLC11A2 and ovarian carcinoma: ELISA results showed that serum SLC11A2 concentrations in patients with a high burden of ovarian cancer (untreated and relapsed) were significantly higher than in women without an ovarian cancer burden (Fig. 8b) The receiver operating curve showed that the best cut-off value for distinguishing ovarian cancer from non-ovarian cancer was: 59.579 pg/ml, and the area under the curve (AUC) was 0.8, which means that SLC11A2 has the potential to act as a serological marker for ovarian cancer (Fig. 8c).